CUTISS Announces First Reconstructive Surgery under Compassionate Use and First U.S. Patient Treated with denovoSkin™
10-10-2024 – In a compassionate reconstructive procedure, denovoSkin™ was grafted on a pediatric patient, marking the first use of denovoSkin™ in the U.S. and the first use of denovoSkin™ in such a surgery.
Dr. Daniela Marino, CEO of CUTISS, said: “We are honored to collaborate with Massachusetts General Hospital. This procedure represents more than just an application of technology – it’s about offering solutions where options are limited and highlights the impact of collaboration between top institutions and innovative emerging companies. At CUTISS, we are dedicated to advancing treatments that can make a real difference in patients’ lives. While the journey is ongoing, we continue to explore the application of denovoSkin™ in burns and reconstructive surgery challenges.”
The four-year-old patient suffered from complex scarring and contractures after the resolution of deep burn wounds affecting 90% of his body, and lacked other therapeutic reconstructive options. Following two denovoSkin™ grafting procedures, the patient is recovering well at MGH. A third procedure is being planned.
denovoSkin (now CUTISS AG) previously accelerated at Wyss Zurich between 2016 to 2022. The team aims to provide patients who suffer from large and deep skin defects with the first personalized and automated skin tissue therapy that is safe, effective, and accessible for children and adults.
Source: CUTISS AG
